We appreciate the interest in our manuscript and the growing attention on cost-effectiveness research.
Van Hout et al. refer to our graphical abstract, which functions as a structural approach to summarize existing economic evaluations for inheritable cardiomyopathies published until April 2021. Thereby, we simply described each study’s conclusion on the cost-effectiveness of a given intervention without including any personal reflections. As the figure itself did indeed not assess each study’s generalizability and transferability, we highlighted the number of included studies per category and concluded, in the graphical abstract as well as in the main text, that more research is needed to guide decision-making [1].
With great interest we read the study by Lim et al. (2022) saying that LVAD therapy may be cost-effective in advanced heart failure patients, which falls beyond the scope of our review as it was published after April 2021 and did not specifically target cardiomyopathy patients [2]. In the future, updated versions of our systematic review will be essential to capture emerging evidence and ensure the continued relevance of the findings.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
